Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Study of Alpelisib (BYL719) in Combination With Carboplatin in Patients With Solid Tumors and HPV+ Squamous Cell Carcinoma

NCT05472220 is registered in ClinicalTrials.gov with Pamela Munster as lead sponsor.

NCT NCT05472220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05472220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Study of Alpelisib (BYL719) in Combination With Carboplatin in Patients With Solid Tumors and HPV+ Squamous Cell Carcinoma
Lead sponsor
Pamela Munster
Phase
Phase 1
Overall status
Withdrawn
Start date
November 1, 2022
Completion date
April 30, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-related squamous cell carcinoma, human papillomavirus-related carcinoma, human papillomavirus-related squamous cell carcinoma, locally advanced malignant solid neoplasm, metastatic malignant solid neoplasm, pik3ca mutation, pik3ca mutation-related tumors, solid tumors, adult